Matrix Mechanotransduction via Yes-Associated Protein in Human Lamina Cribrosa Cells in Glaucoma

Purpose: Extracellular matrix stiffening is characteristic of both aging and glaucoma, and acts as a promoter and perpetuator of pathological fibrotic remodeling. Here, we investigate the role of a mechanosensitive transcriptional coactivator, Yes-associated protein (YAP), a downstream effector of multiple signaling pathways, in lamina cribrosa (LC) cell activation to a profibrotic, glaucomatous state.

Methods: LC cells isolated from glaucomatous human donor eyes (GLC; n = 3) were compared to LC cells from age-matched nonglaucomatous controls (NLC; n = 3) to determine differential YAP expression, protein levels, and proliferation rates. NLC cells were then cultured on soft (4 kPa), and stiff (100 kPa), collagen-1 coated polyacrylamide hydrogel substrates. Quantitative real-time RT-PCR, immunoblotting, and immunofluorescence microscopy were used to measure the expression, activity, and subcellular location of YAP and its downstream targets, respectively. Proliferation rates were examined in NLC and GLC cells by methyl thiazolyl tetrazolium salt assays, across a range of incrementally increased substrate stiffness. Endpoints were examined in the presence or absence of a YAP inhibitor, verteporfin (2 µM).

Results: GLC cells show significantly (P < 0.05) increased YAP gene expression and total-YAP protein compared to NLC cells, with significantly increased proliferation. YAP regulation is mechanosensitive, because NLC cells cultured on pathomimetic, stiff substrates (100 kPa) show significantly upregulated YAP gene and protein expression, increased YAP phosphorylation at tyrosine 357, reduced YAP phosphorylation at serine 127, increased nuclear pooling, and increased transcriptional target, connective tissue growth factor. Accordingly, myofibroblastic markers, α-smooth muscle actin (α-SMA) and collagen type I, alpha 1 (Col1A1) are increased. Proliferation rates are elevated on 50 kPa substrates and tissue culture plastic. Verteporfin treatment significantly inhibits YAP-mediated cellular activation and proliferation despite a stiffened microenvironment.

Conclusions: These data demonstrate how YAP plays a pivotal role in LC cells adopting a profibrotic and proliferative phenotype in response to the stiffened LC present in aging and glaucoma. YAP provides an attractive and novel therapeutic target, and its inhibition via verteporfin warrants further clinical investigation.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:63

Enthalten in:

Investigative ophthalmology & visual science - 63(2022), 1 vom: 03. Jan., Seite 16

Sprache:

Englisch

Beteiligte Personen:

Murphy, Rory [VerfasserIn]
Irnaten, Mustapha [VerfasserIn]
Hopkins, Alan [VerfasserIn]
O'Callaghan, Jeffrey [VerfasserIn]
Stamer, W Daniel [VerfasserIn]
Clark, Abbot F [VerfasserIn]
Wallace, Deborah [VerfasserIn]
O'Brien, Colm J [VerfasserIn]

Links:

Volltext

Themen:

63231-63-0
EC 2.7.10.2
Journal Article
Proto-Oncogene Proteins c-yes
RNA
Research Support, Non-U.S. Gov't
YAP-Signaling Proteins
YES1 protein, human

Anmerkungen:

Date Completed 18.02.2022

Date Revised 18.02.2022

published: Print

Citation Status MEDLINE

doi:

10.1167/iovs.63.1.16

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM335501575